LOCALLY ADVANCED UROTHELIAL CARCINOMA

This study tests an experimental drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the safest dose and see if the drug can shrink tumors. About 310 adults whose cancer has not respon…

This early-phase trial tests a combination of three drugs (tremelimumab, durvalumab, and belinostat) in people with advanced bladder cancer that has spread or cannot be removed surgically. The main goal is to find the safest dose and understand side effects. About 9 adults who ha…

This study tests whether giving the drug enfortumab vedotin less often can still control advanced bladder cancer while reducing side effects. About 60 adults with metastatic or locally advanced urothelial carcinoma will receive the drug alone or with pembrolizumab. The goal is to…

This study tests a combination of two drugs, tazemetostat and pembrolizumab, in 30 people with advanced bladder cancer that has spread. The goal is to find the best dose and see if the combo works better than pembrolizumab alone. Participants must have had prior chemotherapy that…

This Phase 3 trial tests whether the immunotherapy drug pembrolizumab, given after surgery, helps people with muscle-invasive or locally advanced bladder cancer live longer without the cancer returning. About 739 participants are randomly assigned to receive pembrolizumab or just…

This study was designed to test a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) in people with advanced bladder cancer who had not received prior treatment. The goal was to see if the combination was safe and helped control the cancer. However, the tri…

This study is for people with advanced bladder cancer that has spread or cannot be removed by surgery. It tests a combination of two or three drugs (MK-2870, enfortumab vedotin, and pembrolizumab) to see if they are safe and can shrink tumors. The trial has two parts: first check…

This study tests adding propranolol, a blood pressure drug, to standard immunotherapy for people with advanced bladder cancer that has spread. The goal is to see if the combination is safe and helps control the cancer. Only 6 adults took part, and the study is no longer recruitin…

This early-phase trial tests a combination of two drugs—sonidegib and pembrolizumab—in people with advanced solid tumors that have spread. The goal is to find the safest dose of sonidegib when used with pembrolizumab and to see if the pair can shrink tumors. About 36 adults with …

This study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs after about a year without hurting their chances of survival. The goal is to see if stopping early leads to fewer side effects, better quality of life, and lower costs, while still…

This early-phase trial tests a combination of two drugs—erdafitinib and enfortumab vedotin—for people with advanced bladder cancer that has spread and has specific changes in the FGFR2/3 genes. The study includes about 24 adults whose cancer worsened after standard chemotherapy. …

This study looks at whether certain genetic changes in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Researchers are testing tumor samples for specific gene mutations and a protein called CXCL13. The…